Ligand Pharmaceuticals (LGND) reported Q1 core adjusted net income Thursday of $1.33 per diluted share, up from $1.20 a year earlier.
Analysts polled by FactSet expected $1.21.
Revenue for the quarter ended March 31 was $45.3 million, up from $31 million a year earlier.
Analysts surveyed by FactSet expected $38.7 million.
The company said it continues to expect 2025 adjusted diluted EPS between $6.00 and $6.25 on revenue of $180 million to $200 million.
Analysts polled by FactSet expect full-year adjusted EPS of $6.11 and revenue of $190.9 million.
Shares were 0.9% higher in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。